Jennison Associates
MDGL icon

Jennison Associates’s Madrigal Pharmaceuticals MDGL Stock Holding History

Jennison Associates’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-32,987
Closed -$7.99M – 602
2023
Q1 		$7.99M Sell
32,987
-25,969
-44% -$7.08M 0.01% 413
2022
Q4 		$17.1M Sell
58,956
-54,544
-48% -$5.33M 0.02% 340
2022
Q3 		$7.38M Sell
113,500
-68,946
-38% -$4.79M 0.01% 415
2022
Q2 		$13.1M Buy
+182,446
New +$13.4M 0.01% 365
2020
Q3 		– Sell
-177,565
Closed -$20.1M – 664
2020
Q2 		$20.1M Sell
177,565
-47,369
-21% -$4.66M 0.02% 295
2020
Q1 		$15M Sell
224,934
-51,496
-19% -$4.29M 0.02% 291
2019
Q4 		$25.2M Buy
276,430
+741
+0.3% +$71.9K 0.03% 281
2019
Q3 		$23.8M Sell
275,689
-29,204
-10% -$2.74M 0.03% 293
2019
Q2 		$32M Sell
304,893
-6,127
-2% -$656K 0.03% 274
2019
Q1 		$39M Buy
311,020
+29,949
+11% +$3.72M 0.04% 265
2018
Q4 		$31.7M Buy
281,071
+57,700
+26% +$8.93M 0.04% 275
2018
Q3 		$47.8M Buy
223,371
+61,586
+38% +$15.5M 0.04% 260
2018
Q2 		$45.3M Sell
161,785
-66,873
-29% -$11.7M 0.04% 278
2018
Q1 		$26.7M Buy
228,658
+24,458
+12% +$3.02M 0.03% 349
2017
Q4 		$18.7M Buy
+204,200
New +$11.7M 0.02% 411
2015
Q4 		– Sell
-189,208
Closed -$11.5M – 712
2015
Q3 		$11.5M Buy
189,208
+1,069
+0.6% +$77.1K 0.01% 498
2015
Q2 		$14.7M Buy
188,139
+1,363
+0.7% +$114K 0.01% 492
2015
Q1 		$12.7M Buy
186,776
+85,924
+85% +$7.37M 0.01% 486
2014
Q4 		$9.35M Sell
100,852
-4,116
-4% -$426K 0.01% 488
2014
Q3 		$11.1M Buy
104,968
+113
+0.1% +$15.7K 0.01% 476
2014
Q2 		$15M Sell
104,855
-8,869
-8% -$1.3M 0.01% 454
2014
Q1 		$17.2M Buy
113,724
+563
+0.5% +$111K 0.02% 453
2013
Q4 		$20.8M Sell
113,161
-12,203
-10% -$2.23M 0.02% 444
2013
Q3 		$27.7M Buy
125,364
+1,253
+1% +$267K 0.03% 396
2013
Q2 		$21.7M Buy
+124,111
New +$32.4M 0.02% 423

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Jennison Associates's MDGL Position: Q2 2023 in Review

Jennison Associates sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2023, closing a stake of 32,987 shares — an estimated $7.99M sold.

Jennison Associates first reported a position in MDGL in Q2 2013 and held it in 25 quarters. The position peaked at $47.8M in Q3 2018. 208 funds tracked by Wall St. Rank hold MDGL as of Q2 2023.

  • Jennison Associates reported no remaining Madrigal Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Jennison Associates sold 32,987 Madrigal Pharmaceuticals shares in Q2 2023, an estimated $7.99M.
  • Jennison Associates first reported a position in Madrigal Pharmaceuticals in Q2 2013 and held it in 25 quarters.
  • Jennison Associates's Madrigal Pharmaceuticals position peaked at $47.8M in Q3 2018.
  • 208 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2023.

Based on Jennison Associates's 13F filing for Q2 2023, filed 3 Aug 2023.